GLP-1 Market
LLY $1416.54 ▲ +3.1% NVO $40.01 ▲ +2.2% PFE $30.50 ▲ +1.9% VKTX $27.30 ▲ +1.6% KLRA $12.86 ▼ -4.1% GPCR $21.87 ▼ -0.3% RHHBY $61.30 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Bivamelagon

Company
Rhythm Pharmaceuticals, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 31, 2026

Trial details
  • Completed NCT NCT06040372

    A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

    Not yet reported LG Chem 112 participants Est. completion 2022-07-30 1 site Stand-alone
    Other conditions: Obese, Overweight, Healthy
    View official trial listing →
  • Status unknown NCT NCT06041841

    A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity

    Not yet reported LG Chem 4 participants Est. completion 2025-12 2 sites Stand-alone
    Other conditions: POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
    View official trial listing →
  • Completed NCT NCT06046443

    A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

    Not yet reported Rhythm Pharmaceuticals, Inc. 28 participants Est. completion 2026-02-09 10 sites Stand-alone
    Other conditions: Hypothalamic Obesity
    View official trial listing →
  • Enrolling by invitation NCT NCT07156578

    A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

    Not yet reported Rhythm Pharmaceuticals, Inc. 25 participants Est. completion 2028-04-15 9 sites Stand-alone
    Other conditions: Hypothalamic Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Bivamelagon, LB54640

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.